Clinical Trials Browser

Neurofibroma, Neurofibromatosis 1, Neurofibromatoses, Neurofibroma, Plexiform

NCT07407803 2026-04-06

Evaluation of TQ-B3234 Capsules in Patients With Symptomatic, Non-Surgical Type 1 Neurofibromatosis-Associated Plexiform Neurofibromas

Phase 3 Recruiting

177 enrolled

CNS

Neurofibroma, Plexiform

NCT03975829 2026-04-02

Pediatric Long-Term Follow-up and Rollover Study

Phase 4 Active not recruiting

163 enrolled

CNSMyeloid

Astrocytoma, Ganglioneuroma, Glioblastoma, Glioma, Histiocytosis, Langerhans-Cell, Neuroblastoma, Neurofibromatosis 1, Oligodendroglioma, Ganglioglioma, Neurocytoma, Neurofibroma, Plexiform

Clinical Trials

ReNeu

Evaluation of TQ-B3234 Capsules in Patients With Symptomatic, Non-Surgical Type 1 Neurofibromatosis-Associated Plexiform Neurofibromas

Pediatric Long-Term Follow-up and Rollover Study

Real-World Treatment Study of Koselugo (Selumetinib)

Individual Patient Compassionate Use of Mirdametinib

KOMET

INSPIRE-NF1

PEDIA

A Study of Selumetinib in Chinese Paediatric and Adult Subjects With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas (PN)

PAS-004 in Adults Who Have Neurofibromatosis Type 1 With Plexiform Neurofibromas

Follow-up Study to Evaluate the Safety and Efficacy of FCN-159 in Pediatric Participants With Neurofibromatosis Type 1

US Selumetinib Registry

FCN-159 in Adult Patients With Symptomatic, Inoperable Neurofibromatosis Type 1-Related Plexiform Neurofibromas

Study to Evaluate the Safety, Tolerability, PK Characteristics and Anti-tumor Activity of FCN-159 in Adult and Pediatric Participants With Neurofibromatosis Type 1

PROTECT

HL-085 in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas

Study to Investigate Safety, Pharmacokinetic (PK), Pharmacodynamic (PD) and Clinical Activity of Trametinib in Subjects With Cancer or Plexiform Neurofibromas and Trametinib in Combination With Dabrafenib in Subjects With Cancers Harboring V600 Mutations

An Intermediate Access Protocol for Selumetinib for Treatment of Neurofibromatosis Type 1

Efficacy and Safety of RAD001 in Treating Plexiform Neurofibromas (PN) Associated With Neurofibromatosis (NF1)